Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Growth hormone receptor antagonists: potential indications].

A F Muller1, J A Janssen, W W de Herder

  • 1Erasmus Universitair Medisch Centrum, afd. Inwendige Geneeskunde, Dr. Molewaterplein 40, 3015 GD Rotterdam. muller@inw3.azr.nl

Nederlands Tijdschrift Voor Geneeskunde
|February 28, 2001
PubMed
Summary

Pegvisomant, a growth hormone receptor antagonist, effectively treats acromegaly. It shows potential for managing diabetic complications and inhibiting tumor growth, with human studies forthcoming.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EndoBridge 2024: pearls and highlights.

Hormones (Athens, Greece)·2025
Same author

Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs).

Pituitary·2025
Same author

Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).

Pituitary·2024
Same author

EndoBridge 2023: highlights and pearls.

Hormones (Athens, Greece)·2024
Same author

Correction: consensus on criteria for acromegaly diagnosis and remission.

Pituitary·2023
Same author

Consensus on criteria for acromegaly diagnosis and remission.

Pituitary·2023

Area of Science:

  • Endocrinology
  • Oncology
  • Metabolic Diseases

Background:

  • Pegvisomant is a mutated human growth hormone (hGH) analog that antagonizes the hGH receptor.
  • Acromegaly is characterized by excessive hGH production, leading to various health complications.
  • Growth hormone (GH) and its mediator insulin-like growth factor-I (IGF-I) play roles in diabetes complications and tumor growth.

Purpose of the Study:

  • To evaluate pegvisomant's efficacy in treating acromegaly.
  • To explore the potential benefits of GH receptor antagonism in managing diabetes mellitus and its complications.
  • To investigate pegvisomant's anti-tumorigenic effects in preclinical cancer models.

Main Methods:

  • Short-term clinical study in acromegaly patients.

Related Experiment Videos

  • Theoretical assessment of GH antagonism in diabetes.
  • Preclinical animal studies using human colon and breast cancer models.

    • Main Results:

    • Pegvisomant demonstrated short-term efficacy in treating acromegaly.
    • Animal models suggest pegvisomant may mitigate diabetic retinopathy and nephropathy.
    • Pegvisomant significantly reduced tumor growth in animal models of colon and breast cancer.

    Conclusions:

    • Pegvisomant is an effective treatment for acromegaly.
    • Further clinical investigation is warranted for pegvisomant's role in diabetes mellitus and cancer treatment.
    • Pegvisomant holds promise for addressing GH-related pathologies beyond acromegaly.